循环肿瘤DNA早期检测膀胱保留三联治疗后转移进展
本研究回顾性分析32例肌层浸润性膀胱癌患者在三联治疗(TMT)后、任何复发前的血浆循环肿瘤DNA(ctDNA)。中位随访181天,4例(12.5%)ctDNA阳性,其中3例出现影像学转移;28例(87.5%)ctDNA阴性者均无转移。ctDNA阳性检测转移的敏感性100%、特异性93%,中位领先临床诊断138天,且与更差的无转移生存和无复发生存相关(P < .0001)。
要点
- TMT后ctDNA阳性可早于影像学138天预警转移。
- ctDNA阳性者转移风险显著增高,阴性者均未转移。
- 需更大样本验证ctDNA指导的TMT后监测策略。
核心结论
- 血浆ctDNA是TMT后早期检测转移进展的潜在生物标志物,但为假设生成性发现。
研究设计与样本
- 回顾性分析32例接受TMT且至少有一次TMT后、复发前ctDNA检测的肌层浸润性膀胱癌患者。
- 按TMT后ctDNA阳性或阴性分层,采用Kaplan-Meier和Cox回归评估无转移生存和无复发生存。
主要发现
- 中位随访181天(范围24-522天),4例(12.5%)ctDNA阳性,28例(87.5%)ctDNA阴性。
- 4例ctDNA阳性中3例出现影像学转移证据,28例ctDNA阴性者均无转移。
- TMT后6个月ctDNA监测检测转移的敏感性100%、特异性93%。
- ctDNA检测较临床检出转移的中位领先时间为138天。
- ctDNA阳性与更差的无转移生存和无复发生存相关(P < .0001);单变量分析中ctDNA阳性是唯一与更差RFS显著相关的变量(HR 3.53,95% CI:1.11-11.53,P = .03)。
关键数值与推荐
- ctDNA阳性定义:TMT后血浆ctDNA检测为阳性。
- 转移检测性能:敏感性100%、特异性93%(TMT后6个月ctDNA监测)。
- 中位领先时间:138天。
临床怎么用
- TMT后可通过血浆ctDNA监测早期预警转移,比影像学提前约138天。
- ctDNA阳性患者应考虑更密切随访或进一步影像学评估。
- ctDNA阴性患者转移风险低,但仍需常规随访。
局限性
- 回顾性设计,样本量仅32例。
- 随访时间较短(中位181天)。
- 结果为假设生成性,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radical cystectomy and trimodality therapy (TMT) are efficacious treatments for muscle invasive bladder cancer. Novel methods for post-treatment surveillance are needed to detect recurrence. This study assesses the value of plasma circulating tumor DNA (ctDNA) for detection of post-TMT recurrence. MATERIALS AND METHODS: We performed a retrospective ctDNA analysis in 32 patients with at least one post-TMT ctDNA measurement before any disease recurrence. Patients were stratified as post-TMT ctDNA (+) or ctDNA (-) and assessed for metastasis-free survival and recurrence-free survival (RFS) using Kaplan-Meier and Cox regression methods. RESULTS: At a median follow-up of 181 days (range: 24-522) after the first post-TMT ctDNA measurement, 4 patients (12.5%) were ctDNA (+) and 28 patients (87.5%) were ctDNA (-); 3 of 4 ctDNA (+) patients developed radiographic evidence of metastasis. All 28 ctDNA (-) patients were without metastasis. ctDNA positivity correctly identified all metastatic progression with 100% sensitivity and 93% specificity at 6-month post-TMT ctDNA surveillance. Furthermore, ctDNA-based detection preceded clinical detection of metastasis with a median lead time of 138 days. ctDNA (+) status was associated with worse metastasis-free survival (P < .0001) and RFS (P < .0001). In univariable analysis, ctDNA (+) status was the only variable significantly associated with worse RFS (HR 3.53, 95% CI: 1.11-11.53, P = .03). CONCLUSIONS: Plasma ctDNA is a potential biomarker for early detection of metastatic progression after TMT. Our hypothesis-generating findings provide a basis for larger studies to evaluate the utility of ctDNA-guided post-TMT surveillance.
引用
- Zhao D, Khatri VM, Nakashima JY, et al. Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy. J Urol. 2025. PMID: 41231842. doi:10.1097/JU.0000000000004849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。